Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000059.xml
Pneumologie 2024; 78(05): 330-345
DOI: 10.1055/a-1854-2693
DOI: 10.1055/a-1854-2693
Fort- und Weiterbildung
Intensivmedizinische Therapie von COVID-19
COVID-19 in the intensive care unit
Die pathophysiologischen Abläufe des klassischen akuten Lungenversagens (ARDS) und des ARDS aufgrund einer SARS-CoV-2-Infektion (C-ARDS) sind grundsätzlich ähnlich. Beide führen in ihrer Endstrecke der Inflammation zu einer Störung der Blut-Luft-Schranke. Die Behandlungsstrategien für C-ARDS konzentrieren sich, wie beim klassischen ARDS, auf die Unterstützung oder den Ersatz von Organfunktionen und die Vermeidung von Folgeschäden. Der vorliegende Artikel fasst die Behandlungsstrategien auf der Intensivstation zusammen.
Abstract
The acute respiratory failure as well as ARDS (acute respiratory distress syndrome) have challenged clinicians since the initial description over 50 years ago. Various causes can lead to ARDS and therapeutic approaches for ARDS/ARF are limited to the support or replacement of organ functions and the prevention of therapy-induced consequences. In recent years, triggered by the SARS-CoV-2 pathogen, numerous cases of acute lung failure (C-ARDS) have emerged. The pathophysiological processes of classical ARDS and C-ARDS are essentially similar. In their final stages of inflammation, both lead to a disruption of the blood-air barrier. Treatment strategies for C-ARDS, like classical ARDS, focus on supporting or replacing organ functions and preventing consequential damage. This article summarizes the treatment strategies in the intensive care unit.
-
Das klassische ARDS unter scheidet sich kaum in den grundlegenden pathophysiologischen Abläufen von dem ARDS, welches durch SARS-CoV-2 ausgelöst wird.
-
Die Hyperinflammation ist ein wesentlicher Faktor in der Entstehung des ARDS.
-
Die Therapie des ARDS besteht in einer Unterstützung der Organfunktion unter möglicher Vermeidung von Folgeschäden durch die Therapie.
-
Eine antiinflammatorische Therapie mit Kortison sollte bei Sauerstoffpflichtigkeit durchgeführt werden.
-
Bakterielle Ko-Infektionen sollten regelmäßig evaluiert und bei Relevanz adressiert werden, entsprechend den Leitlinien (ambulante und nosokomiale Pneumonie).
-
Eine High-Flow-Sauerstofftherapie oder eine NIV können gegebenenfalls eine invasive Beatmung vermeiden.
-
Bei Einleitung einer HFNC/NIV sollte ein Eskalationsschema festgelegt werden.
-
Unter invasiver Beatmung ist das Ziel beim ARDS eine lungenprotektive Beatmung, mögliche additive Therapiestrategie ist die Bauchlage.
-
Eine mögliche ECMO sollte bei Patienten mit ARDS frühzeitig diskutiert werden, um die Patientenselektion zu verbessern.
-
Eine prophylaktische Antikoagulation sollte bei stationär behandelten Patienten mit COVID-19 durchgeführt werden, sofern keine Indikation für eine Vollantikoagulation besteht.
Publication History
Article published online:
17 May 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Ashbaugh DG, Boyd BD, Petty TL. et al. Acute respiratory distress in adults. Lancet 1967; 290: 319-323 DOI: 10.1016/S0140-6736(67)90168-7.
- 2 Centers for Disease Control and Prevention (CDC). COVID Data Tracker. Accessed February 20, 2024 at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
- 3 Kadkhoda K. Herd Immunity to COVID-19. Am J Clin Pathol 2021; 155: 471-472 DOI: 10.1093/ajcp/aqaa272. (PMID: 33399182)
- 4 Bellani G, Laffey JG, Pham T. et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788-800 DOI: 10.1001/jama.2016.0291.
- 5 Friedrichson B, Mutlak H, Zacharowski K. et al. Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs. Crit Care 2021; 25: 38 DOI: 10.1186/s13054-021-03463-2.
- 6 AWMF. S3-Leitlinie Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz. AWMF-Register-Nr. 001-021. Accessed February 20, 2024 at: https://register.awmf.org/de/leitlinien/detail/001-021
- 7 Fan E, Del Sorbo L, Goligher EC. et al. An official American Thoracic Society/European Society of intensive care medicine/society of critical care medicine clinical practice guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 195: 1253-1263 DOI: 10.1164/rccm.201703-0548ST.
- 8 Grasselli G, Calfee CS, Camporota L. et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 2023; 49: 727-759 DOI: 10.1007/s00134-023-07050-7. (PMID: 37326646)
- 9 Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet 2021; 398: 622-637 DOI: 10.1016/S0140-6736(21)00439-6. (PMID: 34217425)
- 10 Swenson KE, Swenson ER. Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury. Crit Care Clin 2021; 37: 749-776 DOI: 10.1016/j.ccc.2021.05.003. (PMID: 34548132)
- 11 Xu ZS, Shu T, Kang L. et al. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Signal Transduct Target Ther 2020; 5: 100 DOI: 10.1038/s41392-020-0211-1.
- 12 Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 2022; 20: 270-284 DOI: 10.1038/s41579-022-00713-0. (PMID: 35354968)
- 13 Mackman N, Antoniak S, Wolberg AS. et al. Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler Thromb Vasc Biol 2020; 40: 2033-2044 DOI: 10.1161/ATVBAHA.120.314514.
- 14 Bonaventura A, Vecchié A, Dagna L. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21: 319-329 DOI: 10.1038/s41577-021-00536-9. (PMID: 33824483)
- 15 Lannon M, Duda T, Greer A. et al. Intracranial hemorrhage in patients treated for SARS-CoV-2 with extracorporeal membrane oxygenation: A systematic review and meta-analysis. J Crit Care 2023; 77: 154319 DOI: 10.1016/j.jcrc.2023.154319.
- 16 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475-481 DOI: 10.1016/S2213-2600(20)30079-5.
- 17 Xie Y, Bowe B, Maddukuri G. et al. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. BMJ 2020; 371: m4677 DOI: 10.1136/bmj.m4677.
- 18 Francone M, Iafrate F, Masci GM. et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020; 30: 6808-6817 DOI: 10.1007/s00330-020-07033-y.
- 19 Ranieri VM, Rubenfeld GD, Thompson BT. et al. Acute respiratory distress syndrome: The Berlin definition. JAMA 2012; 307: 2526-2533 DOI: 10.1001/jama.2012.5669. (PMID: 22797452)
- 20 Matthay MA, Thompson BT, Ware LB. The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?. Lancet Respir Med 2021; 9: 933-936 DOI: 10.1016/S2213-2600(21)00105-3. (PMID: 33915103)
- 21 Palmer E, Post B, Klapaukh R. et al. The Association between Supraphysiologic Arterial Oxygen Levels and Mortality in Critically Ill Patients. A Multicenter Observational Cohort Study. Am J Respir Crit Care Med 2019; 200: 1373-1380 DOI: 10.1164/rccm.201904-0849OC.
- 22 Semler MW, Casey JD, Lloyd BD. et al. Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation. N Engl J Med 2022; 387: 1759-1769 DOI: 10.1056/NEJMoa2208415. (PMID: 36278971)
- 23 Schjørring OL, Klitgaard TL, Perner A. et al. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure. N Engl J Med 2021; 384: 1301-1311 DOI: 10.1056/NEJMoa2032510. (PMID: 33471452)
- 24 Zhao X, Xiao H, Dai F. et al. Classification and effectiveness of different oxygenation goals in mechanically ventilated critically ill patients: network meta-analysis of randomised controlled trials. Eur Respir J 2021; 58: 2002928 DOI: 10.1183/13993003.02928-2020. (PMID: 33632796)
- 25 AWMF. S3-Leitlinie Empfehlungen zur Therapie von Patienten mit COVID-19. AWMF-Register-Nr. 113-001. Accessed February 20, 2024 at: https://register.awmf.org/assets/guidelines/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2023-03.pdf
- 26 Amato MB, Barbas CS, Medeiros DM. et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338: 347-354 DOI: 10.1056/NEJM199802053380602.
- 27 Badulak J, Antonini MV, Stead CM. et al. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization. ASAIO Journal 2021; 67: 485-495 DOI: 10.1097/MAT.0000000000001422.
- 28 AWMF. S2k-Leitlinie Nichtinvasive Beatmung als Therapie der akuten respiratorischen Insuffizien. AWMF-Register-Nr. 020-004. Accessed February 20, 2024 at: https://register.awmf.org/de/leitlinien/detail/020-004
- 29 Karagiannidis C, Hentschker C, Westhoff M. et al. Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. PLoS One 2022; 17: e0262315 DOI: 10.1371/journal.pone.0262315. (PMID: 35030205)
- 30 Camous L, Pommier JD, Martino F. et al. Very late intubation in COVID-19 patients: a forgotten prognosis factor?. Crit Care 2022; 26: 89 DOI: 10.1186/s13054-022-03966-6.
- 31 Grieco DL, Menga LS, Cesarano M. et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure. JAMA 2021; 325: 1731 DOI: 10.1001/jama.2021.4682.
- 32 Rosén J, Oelreich E von, Fors D. et al. Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial. Crit Care 2021; 25: 209 DOI: 10.1186/s13054-021-03602-9.
- 33 Ehrmann S, Li J, Ibarra-Estrada M. et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med 2021; 9: 1387-1395 DOI: 10.1016/S2213-2600(21)00356-8. (PMID: 34425070)
- 34 Alhazzani W, Parhar KKS, Weatherald J. et al. Effect of Awake Prone Positioning on Endotracheal Intubation in Patients with COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial. JAMA 2022; 327: 2104-2113 DOI: 10.1001/jama.2022.7993. (PMID: 35569448)
- 35 Gattinoni L, Carlesso E, Caironi P. Stress and strain within the lung. Curr Opin Crit Care 2012; 18: 42-47 DOI: 10.1097/MCC.0b013e32834f17d9. (PMID: 22157254)
- 36 Slutsky AS, Ranieri VM. Ventilator-Induced Lung Injury. N Engl J Med 2013; 369: 2126-2136 DOI: 10.1056/NEJMra1208707. (PMID: 24283226)
- 37 Jardin F, Vieillard-Baron A. Is there a safe plateau pressure in ARDS? The right heart only knows. Intensive Care Med 2007; 33: 444-447 DOI: 10.1007/s00134-007-0552-z.
- 38 ARDS net. NIH NHLBI ARDS Clinical Network Mechanical Ventilation Protocol Summary. Accessed February 20, 2024 at: http://www.ardsnet.org/files/ventilator_protocol_2008-07.pdf
- 39 National Institutes of Health (NIH). COVID-19 Treatment Guidelines. Accessed February 20, 2024 at: https://www.covid19treatmentguidelines.nih.gov
- 40 Beitler JR, Sarge T, Banner-Goodspeed VM. et al. Effect of Titrating Positive End-Expiratory Pressure (PEEP) with an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-F io 2 Strategy on Death and Days Free from Mechanical Ventilation among Patients with Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA 2019; 321: 846-857 DOI: 10.1001/jama.2019.0555.
- 41 Cavalcanti AB, Suzumura ÉA, Laranjeira LN. et al. Effect of lung recruitment and titrated Positive End-Expiratory Pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome – A randomized clinical trial. JAMA 2017; 318: 1335-1345 DOI: 10.1001/jama.2017.14171.
- 42 Pintado MC, Pablo R de, Trascasa M. et al. Individualized PEEP setting in subjects with ARDS: A randomized controlled pilot study. Respir Care 2013; 58: 1416-1423 DOI: 10.4187/respcare.02068.
- 43 Wendel Garcia PD, Caccioppola A, Coppola S. et al. Latent class analysis to predict intensive care outcomes in Acute Respiratory Distress Syndrome: a proposal of two pulmonary phenotypes. Crit Care 2021; 25: 154 DOI: 10.1186/s13054-021-03578-6.
- 44 Khokher W, Malhas SE, Beran A. et al. Inhaled Pulmonary Vasodilators in COVID-19 Infection: A Systematic Review and Meta-Analysis. J Intensive Care Med 2022; 37: 1370-1382 DOI: 10.1177/08850666221118271. (PMID: 35915994)
- 45 Sameed M, Meng Z, Marciniak ET. EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy?. Breathe 2019; 15: 244-246 DOI: 10.1183/20734735.0363-2018. (PMID: 31508163)
- 46 Combes A, Peek GJ, Hajage D. et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med 2020; 46: 2048-2057 DOI: 10.1007/s00134-020-06248-3. (PMID: 33021684)
- 47 Karagiannidis C, Bein T, Welte T. ECMO during the COVID-19 pandemic: moving from rescue therapy to more reasonable indications. Eu Respir J 2022; 59: 2103262 DOI: 10.1183/13993003.03262-2021.
- 48 Extracorporeal Life Support Organization (ELSO). General Guidelines for All ECLS Cases. 2017 Accessed February 20, 2024 at: https://www.elso.org/ecmo-resources/elso-ecmo-guidelines.aspx
- 49 Anselmi A, Mansour A, Para M. et al. Veno-Arterial Extracorporeal Membrane Oxygenation for Circulatory Failure in COVID-19 Patients: Insights from the ECMOSARS Registry. Eur J Cardiothorac Surg 2023; 64: ezad229 DOI: 10.1093/ejcts/ezad229.
- 50 Kannapadi NV, Jami M, Premraj L. et al. Neurological Complications in COVID-19 Patients With ECMO Support: A Systematic Review and Meta-Analysis. Heart Lung Circ 2022; 31: 292-298 DOI: 10.1016/j.hlc.2021.10.007.
- 51 Giani M, Martucci G, Madotto F. et al. Prone Positioning during Venovenous Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome A Multicenter Cohort Study and Propensity-matched Analysis. Ann Am Thorac Soc 2021; 18: 495-501 DOI: 10.1513/AnnalsATS.202006-625OC.
- 52 Massart N, Guervilly C, Mansour A. et al. Impact of Prone Position in COVID-19 Patients on Extracorporeal Membrane Oxygenation*. Crit Care Med 2023; 51: 36-46 DOI: 10.1097/CCM.0000000000005714. (PMID: 36519982)
- 53 Dreier E, Malfertheiner MV, Dienemann T. et al. ECMO in COVID-19 – prolonged therapy needed? A retrospective analysis of outcome and prognostic factors. Perfusion (United Kingdom) 2021; 36: 582-591 DOI: 10.1177/0267659121995997. (PMID: 33612020)
- 54 Schmidt M, Hajage D, Lebreton G. et al. Prone Positioning During Extracorporeal Membrane Oxygenation in Patients With Severe ARDS: The PRONECMO Randomized Clinical Trial. JAMA 2023; 330: 2343-2353 DOI: 10.1001/jama.2023.24491.
- 55 Silversides JA, Major E, Ferguson AJ. et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 2017; 43: 155-170 DOI: 10.1007/s00134-016-4573-3. (PMID: 27734109)
- 56 Santoriello D, Khairallah P, Bomback AS. et al. Postmortem Kidney Pathology Findings in Patients with COVID-19. J Am Soc Nephrol 2020; 31: 2158-2167 DOI: 10.1681/ASN.2020050744.
- 57 Kudose S, Batal I, Santoriello D. et al. Kidney Biopsy Findings in Patients with COVID-19. J Am Soc Nephrol 2020; 31: 1959-1968 DOI: 10.1681/ASN.2020060802.
- 58 Moss M, Huang DT, Brower RG. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med 2019; 380: 1997-2008 DOI: 10.1056/NEJMoa1901686. (PMID: 31112383)
- 59 AWMF. S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie). AWMF-Register-Nr. 001-012. Accessed February 20, 2024 at: https://register.awmf.org/de/leitlinien/detail/001-012
- 60 Langford BJ, So M, Raybardhan S. et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26: 1622-1629 DOI: 10.1016/j.cmi.2020.07.016.
- 61 Garcia-Vidal C, Sanjuan G, Moreno-García E. et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27: 83-88 DOI: 10.1016/j.cmi.2020.07.041.
- 62 Urban M, Meilinger M, Hermann M. et al. Nosokomiale Pneumonie und beatmungsassoziierte Krankenhauserreger. Anästhesie Nachr 2022; 4: 243-253 DOI: 10.1007/s44179-022-00078-y.
- 63 Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020; 505: 190-191 DOI: 10.1016/j.cca.2020.03.004. (PMID: 32145275)
- 64 Pink I, Raupach D, Fuge J. et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection 2021; 49: 935-943 DOI: 10.1007/s15010-021-01615-8. (PMID: 34021897)
- 65 Wagner C, Griesel M, Mikolajewska A. et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8: CD014963 DOI: 10.1002/14651858.CD014963. (PMID: 34396514)
- 66 Horby P, Shen Lim W, Emberson JR. RECOVERY Collaborative Group. et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384: 693-704 DOI: 10.1056/NEJMoa2021436.
- 67 Villar J, Ferrando C, Martínez D. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8: 267-276 DOI: 10.1016/S2213-2600(19)30417-5. (PMID: 32043986)
- 68 Ghosn L, Chaimani A, Evrenoglou T. et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev 2021; 3: CD013881 DOI: 10.1002/14651858.CD013881. (PMID: 37260086)
- 69 Gordon AC, Mouncey PR, Al-Beidh F. REMAP-CAP Investigators. et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021; 384: 1491-1502 DOI: 10.1056/NEJMoa2100433. (PMID: 37012484)
- 70 Gottlieb RL, Vaca CE, Paredes R. et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med 2022; 386: 305-315 DOI: 10.1056/NEJMoa2116846. (PMID: 34937145)
- 71 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med 2020; 383: 1813-1826 DOI: 10.1056/NEJMoa2007764. (PMID: 32445440)
- 72 Pan H, Peto R, Henao-Restrepo AM. WHO Solidarity Trial Consortium. et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384: 497-511 DOI: 10.1056/NEJMoa2023184. (PMID: 33264556)
- 73 ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators. et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021; 385: 790-802 DOI: 10.1056/NEJMoa2105911. (PMID: 34351722)
- 74 Spyropoulos AC, Goldin M, Giannis D. et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Intern Med 2021; 181: 1612 DOI: 10.1001/jamainternmed.2021.6203. (PMID: 34617959)
- 75 Florescu S, Stanciu D, Zaharia M. et al. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA 2023; 329: 39 DOI: 10.1001/jama.2022.23257.